-
Interview with Dr. John Marshall and Dr. Tony Shields on MI FOLFOXai™
In this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa.
Category: News
-
Ruesch Center Targets Gastrointestinal Cancers
While her husband received treatment, Jeanne Ruesch saw firsthand the dishearteningly protracted pace of gastrointestinal cancer research. She was inspired by the care that she and her husband received from oncologist John Marshall, MD, but at the same time recognized a gaping need for a better understanding of GI cancers and how to treat them.
Category: News
-
Disrupting the cellular process that promotes pancreatic cancer’s deadly growth
In research part-funded by the Ruesch Center and published today in Gastroenterology, Georgetown’s Peran, Byers, et al. find a possible biomarker and mechanism for gemcitabine response in pancreas cancer.
Category: News
-
OncLive® Partners with The Ruesch Center to Host the 11th Annual Ruesch Center Symposium
Finding more cures for GI cancer will only come through innovative research, and we are so proud to be featuring both the most up-to-date science and the projects of tomorrow. And as a bonus, we will be premiering our new POWER program, a short course in precision medicine to close our knowledge gaps in this rapidly evolving field,” said John L. Marshall, M.D., director, The Ruesch Center for the Cure of GI Cancers.
Category: News
-
Dr. Marshall Recognizes Need for Collaboration During Pancreatic Cancer Awareness Month
In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.
Category: News
-
Oncology Peer Review On-The-Go: Molecular Profiling in Metastatic Colorectal Cancer
This episode of “Oncology Peer Review On-The-Go” examines a review article published in the September issue of the journal ONCOLOGY. The article, “Molecular Profiling in Metastatic Colorectal Cancer,” was written by Samantha Armstrong, MD, Rita Malley, MS, and Benjamin Weinberg MD. For the article’s response perspective, CancerNetwork spoke with John Marshall, MD, of the Georgetown Lombardi Comprehensive Cancer Center. Dr. Marshall discussed the cost, quality of care, accessibility and more regarding molecular profiling and precision medicine.
Category: News
-
Molecular Profiling for Metastatic Colorectal Cancer and the Future of the Disease
“A better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape,” Dr. Benjamin Weinberg and Dr. Samantha Armstrong explain.
Category: News
-
Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management
Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.
Category: News
-
Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types
Learn from the experts including Dr. John Marshall, Dr. Jamie Chaft, MD and Scot Niglio, MD, about current and emerging immuno-oncology biomarkers to guide selection of optimal cancer treatment across tumor types. Participate in the interactive CCO Webinar or watch the on-demand Webcast and download the slides. Listen to a podcast for answers to FAQs asked during the live Webinar.
Category: News
-
No-Visitor Policies Are Bad Medicine
According to Dr. John Marshall, “Cancer care is not elective; it has to keep going. One of the worst policies for our patients right now is this no-visitor policy. You are coming for a treatment, a clinic visit, or, worse yet, admitted to the hospital for end-of-life care or for some complex medical procedure related to your cancer, and yet you can’t have a caregiver, an advocate, sitting next to you in your room.”
Category: News